Selected research
Industry Research
Integrin Alpha V Industry Research Report 2026
Market perspective
The global Integrin Alpha V market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Integrin Alpha V market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Integrin Alpha V market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Integrin Alpha V market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Integrin Alpha V include Merck & Co Inc, Biogen Inc, Vascular Pharmaceuticals Inc, SciFluor Life Sciences LLC, Morphic Therapeutic Inc, Merck KGaA, MedImmune LLC, Factor Therapeutics Ltd and BioMAS Ltd. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Integrin Alpha V market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Integrin Alpha V.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Integrin Alpha V Market by Company
Merck & Co Inc
Biogen Inc
Vascular Pharmaceuticals Inc
SciFluor Life Sciences LLC
Morphic Therapeutic Inc
Merck KGaA
MedImmune LLC
Factor Therapeutics Ltd
BioMAS Ltd
Integrin Alpha V Segment by Type
MK-0429
C-16Y
AC-301
264-RAD
Others
Integrin Alpha V Segment by Application
Ophthalmology
Respiratory
Metabolic Disorders
Infectious Disease
Others
Integrin Alpha V Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Integrin Alpha V market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Integrin Alpha V and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Integrin Alpha V.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Integrin Alpha V companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- MK-0429
- C-16Y
- AC-301
- 264-RAD
- Others
Applications
- Ophthalmology
- Respiratory
- Metabolic Disorders
- Infectious Disease
- Others
Companies covered
- Merck & Co Inc
- Biogen Inc
- Vascular Pharmaceuticals Inc
- SciFluor Life Sciences LLC
- Morphic Therapeutic Inc
- Merck KGaA
- MedImmune LLC
- Factor Therapeutics Ltd
- BioMAS Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Integrin Alpha V by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 MK-0429
- 2.2.3 C-16Y
- 2.2.4 AC-301
- 2.2.5 264-RAD
- 2.2.6 Others
- 2.3 Integrin Alpha V by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Ophthalmology
- 2.3.3 Respiratory
- 2.3.4 Metabolic Disorders
- 2.3.5 Infectious Disease
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Integrin Alpha V Breakdown Data by Type
- 3.1 Global Integrin Alpha V Historic Market Size by Type (2021-2026)
- 3.2 Global Integrin Alpha V Forecasted Market Size by Type (2027-2032)
4 Integrin Alpha V Breakdown Data by Application
- 4.1 Global Integrin Alpha V Historic Market Size by Application (2021-2026)
- 4.2 Global Integrin Alpha V Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Integrin Alpha V Market Perspective (2021-2032)
- 5.2 Global Integrin Alpha V Growth Trends by Region
- 5.2.1 Global Integrin Alpha V Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Integrin Alpha V Historic Market Size by Region (2021-2026)
- 5.2.3 Integrin Alpha V Forecasted Market Size by Region (2027-2032)
- 5.3 Integrin Alpha V Market Dynamics
- 5.3.1 Integrin Alpha V Industry Trends
- 5.3.2 Integrin Alpha V Market Drivers
- 5.3.3 Integrin Alpha V Market Challenges
- 5.3.4 Integrin Alpha V Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Integrin Alpha V Players by Revenue
- 6.1.1 Global Top Integrin Alpha V Players by Revenue (2021-2026)
- 6.1.2 Global Integrin Alpha V Revenue Market Share by Players (2021-2026)
- 6.2 Global Integrin Alpha V Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Integrin Alpha V Head Office and Area Served
- 6.4 Global Integrin Alpha V Players, Product Type & Application
- 6.5 Global Integrin Alpha V Manufacturers Established Date
- 6.6 Global Integrin Alpha V Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Integrin Alpha V Market Size (2021-2032)
- 7.2 North America Integrin Alpha V Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Integrin Alpha V Market Size by Country (2021-2026)
- 7.4 North America Integrin Alpha V Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Integrin Alpha V Market Size (2021-2032)
- 8.2 Europe Integrin Alpha V Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Integrin Alpha V Market Size by Country (2021-2026)
- 8.4 Europe Integrin Alpha V Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Integrin Alpha V Market Size (2021-2032)
- 9.2 Asia-Pacific Integrin Alpha V Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Integrin Alpha V Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Integrin Alpha V Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Integrin Alpha V Market Size (2021-2032)
- 10.2 South America Integrin Alpha V Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Integrin Alpha V Market Size by Country (2021-2026)
- 10.4 South America Integrin Alpha V Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Integrin Alpha V Market Size (2021-2032)
- 11.2 Middle East & Africa Integrin Alpha V Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Integrin Alpha V Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Integrin Alpha V Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck & Co Inc
- 12.1.1 Merck & Co Inc Company Information
- 12.1.2 Merck & Co Inc Business Overview
- 12.1.3 Merck & Co Inc Revenue in Integrin Alpha V Business (2021-2026)
- 12.1.4 Merck & Co Inc Integrin Alpha V Product Portfolio
- 12.1.5 Merck & Co Inc Recent Developments
- 12.2 Biogen Inc
- 12.2.1 Biogen Inc Company Information
- 12.2.2 Biogen Inc Business Overview
- 12.2.3 Biogen Inc Revenue in Integrin Alpha V Business (2021-2026)
- 12.2.4 Biogen Inc Integrin Alpha V Product Portfolio
- 12.2.5 Biogen Inc Recent Developments
- 12.3 Vascular Pharmaceuticals Inc
- 12.3.1 Vascular Pharmaceuticals Inc Company Information
- 12.3.2 Vascular Pharmaceuticals Inc Business Overview
- 12.3.3 Vascular Pharmaceuticals Inc Revenue in Integrin Alpha V Business (2021-2026)
- 12.3.4 Vascular Pharmaceuticals Inc Integrin Alpha V Product Portfolio
- 12.3.5 Vascular Pharmaceuticals Inc Recent Developments
- 12.4 SciFluor Life Sciences LLC
- 12.4.1 SciFluor Life Sciences LLC Company Information
- 12.4.2 SciFluor Life Sciences LLC Business Overview
- 12.4.3 SciFluor Life Sciences LLC Revenue in Integrin Alpha V Business (2021-2026)
- 12.4.4 SciFluor Life Sciences LLC Integrin Alpha V Product Portfolio
- 12.4.5 SciFluor Life Sciences LLC Recent Developments
- 12.5 Morphic Therapeutic Inc
- 12.5.1 Morphic Therapeutic Inc Company Information
- 12.5.2 Morphic Therapeutic Inc Business Overview
- 12.5.3 Morphic Therapeutic Inc Revenue in Integrin Alpha V Business (2021-2026)
- 12.5.4 Morphic Therapeutic Inc Integrin Alpha V Product Portfolio
- 12.5.5 Morphic Therapeutic Inc Recent Developments
- 12.6 Merck KGaA
- 12.6.1 Merck KGaA Company Information
- 12.6.2 Merck KGaA Business Overview
- 12.6.3 Merck KGaA Revenue in Integrin Alpha V Business (2021-2026)
- 12.6.4 Merck KGaA Integrin Alpha V Product Portfolio
- 12.6.5 Merck KGaA Recent Developments
- 12.7 MedImmune LLC
- 12.7.1 MedImmune LLC Company Information
- 12.7.2 MedImmune LLC Business Overview
- 12.7.3 MedImmune LLC Revenue in Integrin Alpha V Business (2021-2026)
- 12.7.4 MedImmune LLC Integrin Alpha V Product Portfolio
- 12.7.5 MedImmune LLC Recent Developments
- 12.8 Factor Therapeutics Ltd
- 12.8.1 Factor Therapeutics Ltd Company Information
- 12.8.2 Factor Therapeutics Ltd Business Overview
- 12.8.3 Factor Therapeutics Ltd Revenue in Integrin Alpha V Business (2021-2026)
- 12.8.4 Factor Therapeutics Ltd Integrin Alpha V Product Portfolio
- 12.8.5 Factor Therapeutics Ltd Recent Developments
- 12.9 BioMAS Ltd
- 12.9.1 BioMAS Ltd Company Information
- 12.9.2 BioMAS Ltd Business Overview
- 12.9.3 BioMAS Ltd Revenue in Integrin Alpha V Business (2021-2026)
- 12.9.4 BioMAS Ltd Integrin Alpha V Product Portfolio
- 12.9.5 BioMAS Ltd Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst